Tag:Roche

Hetero gets approval to make Roche’s tocilizumab in India under the brand name Tocira

By this month’s end, Hetero is planning on making tocilizumab in India under the brand name Tocira. Hetero is...

Roche’s Actemra may see high demand and short supply due to COVID delta variant

The infused form of Genentech’s arthritis drug, tocilizumab (Roche Actemra), which is being used as a therapy for severe COVID-19 cases, is...

Softbank now has $5B stake in Roche for its ability to develop drugs using data

The Japanese multinational group, SoftBank Group Corp., has quietly invested $5 billion in Roche Holding AG, having high hopes with the company’s...

Roche relying on Polivy’s $2B potential to weather biosimilar storm

To help withstand brutal attacks from biosimilars for the cancer troika  ̶   Rituxan, Herceptin and Avastin  ̶  Roche relying has been relying...

Roche to lay off 300 to 400 employees in product development jobs

Roche’s executives, including CMO (Chief Medical Officer) Levi Garraway, claimed in a recorded video conference with staff acquired by Swiss Newspaper Blick

Clinical-stage Pieris Pharma signs agreement with Genentech for respiratory and ophthalmology therapies

As if the partnerships with Boston Pharmaceuticals, AstraZeneca, and Servier were not enough for the biotech firm,

Roche is the biggest R&D spender investing 23.8% of its total sales

Last year, the research and development expenditures have been increased by 11% to $86.3 billion by the 11 top pharmaceutical companies of the world.

Latest news

Repair Biotechnologies to Leverage Genevant Sciences’ LNP Technology for Atherosclerosis Treatment

Repair Biotechnologies has joined forces with Swiss company Genevant Sciences to gain access to Genevant’s lipid nanoparticle (LNP) technology...
- Advertisement -

AbbVie’s Parkinson’s Drug Meets Phase 3 Trial Goal

AbbVie has disclosed that its late-stage monotherapy prospect substantially decreased the impact of the condition in patients as contrasted...

AstraZeneca Expands AI-Powered Immuno-Oncology Research Partnership with Immunai

Immunai, a biotechnology company based in New York, has partnered with AstraZeneca in a multiyear endeavor to try and...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm